Discovery Candidates
DISCOVERY PIPELINE
IMMUNO-ONCOLOGY TARGET
Anti-CD39 (AB598)
Exo-nucleotidase
CD39 is a key enzyme in removing ATP from the tumor microenvironment; increased ATP may enhance the adaptive immune response against tumors.1
Additional undisclosed targets.
CANCER CELL INTRINSIC TARGET
AXL Inhibitor (AB801)
Tyrosine kinase
AXL overexpression is associated with tumor resistance to chemotherapy
and immunotherapy drugs.2
Additional undisclosed targets.
References: 1. Moesta et al. Targeting CD39 in Cancer. Nat Rev Immunol. Volume 20, pages 739–755 (2020). 2. Axelrod HD, Valkenburg KC, Amend SR, et al. AXL is a putative tumor suppressor and dormancy regulator in prostate cancer. Mol Cancer Res. 2019;17(2):356-369.
